OncoVista Innovative Therapies, Inc.

OTC: OVIT · Healthcare · Biotechnology

PublicHQ San Antonio, TX · BexarCIK 0001094847Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH —DQ 23GM —SS 28

v0.1 · 25/100 weight · pillars only

↑ listing tenure, filing timeliness · ↓ return on assets, balance-sheet leverage

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$2.5M

Employees

Market cap

$2.4k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02014

Net income-$2.5M-$2.5M2014

Operating income-$2.5M-$2.5M2014

Total assets$12.5k$12.5k2014

Liabilities$5.7M$5.7M2014

Equity-$5.7M-$5.7M2014

Revenue trend

FY2011 – FY2014 · USD

FY11

FY12

FY13

FY14

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

OncoVista Innovative Therapies, Inc. booked $0 in FY2014 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Khiron Life Sciences Corp.——Longport, Inc.——Regnum Corp.——Global Hemp Group Inc.——

Neighbors

Bexar →

Valero Energy Corporation$122.7B68B Cullen/Frost Bankers, Inc.$121.6M74B Victory Capital Holdings, Inc.$1.3B75B+Rackspace Technology, Inc.$2.7B49D XPEL, Inc.$476.2M66B Biglari Holdings Inc.$395.3M50D

Key facts

CEOAlexander L. Weis

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Antonio, TX

ExchangeOTC: OVIT

Employees2

IPO date2007-10-26

Latest filings

10-Q2015-11-12 10-Q2015-08-14 10-Q2015-05-15 10-K2015-04-15 10-Q2014-11-13 10-Q2014-08-12 10-Q2014-05-09 10-K2014-04-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.